Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome

• Main Authors: Yucai Wang, Sutapa Sinha, Linda E. Wellik, Charla R. Secreto, Karen L. Rech, Timothy G. Call, Sameer A. Parikh, Saad S. Kenderian, Eli Muchtar, Suzanne R. Hayman, Amber B. Koehler, Daniel L. Van Dyke, Jose F. Leis, Susan L. Slager, Haidong Dong, Neil E. Kay, Rong He, Wei Ding
• Format: Article
• Language: English
• Published: Nature Publishing Group 2021-05-01
• Series: Blood Cancer Journal
• Online Access: https://doi.org/10.1038/s41408-021-00477-5

Abstract Richter syndrome (RS) refers to transformation of chronic lymphocytic leukemia (CLL) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. RS is known to be associated with a number of genetic alterations such as TP53 and NOTCH1 mutations. However, it is unclear what immune microenvironment changes are associated with RS. In this study, we analyzed expression of immune checkpoint molecules and infiltration of immune cells in nodal samples, and peripheral blood T-cell diversity in 33 CLL and 37 RS patients. Compared to CLL, RS nodal tissue had higher PD-L1 expression in histiocytes and dendritic cells (median 16.6% vs. 2.8%, P < 0.01) and PD1 expression in neoplastic B cells (median 26.0% vs. 6.2%, P < 0.01), and higher infiltration of FOXP3-positive T cells (median 1.7% vs. 0.4%, P < 0.01) and CD163-positive macrophages (median 23.4% vs. 9.1%, P < 0.01). In addition, peripheral blood T-cell receptor clonality was significantly lower in RS vs. CLL patients (median [25th–75th], 0.107 [0.070–0.209] vs. 0.233 [0.111–0.406], P = 0.046), suggesting that T cells in RS patients were significantly more diverse than in CLL patients. Collectively these data suggest that CLL and RS have distinct immune signatures. Better understanding of the immune microenvironment is essential to improve immunotherapy efficacy in CLL and RS.